What Percentage Of Its Revenue Could J&J Lose Solely Due To Patent Losses Over The Next 5 Years?
- J&J Could Lose ~ 25% Of Its Pharma Revenue Due To Patent Losses By 2020
- The Gap Will Be Filled By Growing & Pipeline Drugs
The CAGR calculations assume ~10% annual revenue decline for Remicade and ~15%-20% annual revenue decline for other drugs following their respective patent expiry
Have more questions about Johnson & Johnson? See the links below.
- How J&J’s Increased Focus On Pharmaceuticals Has Helped Its Financials?
- Drugs, Devices, Consumer: What’s Johnson & Johnson’s Revenue and Earnings breakdown?
- What’s J&J’s Fundamental Value Based On Expected 2015 Results?
- How Increased Focus On Pharmaceuticals In The Last 5 Years Has Helped J&J?
- By How Much Can J&J’s Revenue And EBITDA Grow Over The Next 3 Years?
- What’s J&J’s Fundamental Value Based On Expected 2015 Results?
- How Much Revenues Can J&J’s Phase 3 Pipeline Add By 2020?
- If Remicade Biosimilar Hits The U.S. Market In 2017, Does J&J Face Any Meaningful EPS Decline?
Note: The figures mentioned are approximate values to help our readers remember and grasp the concept more intuitively. For accurate figures, please refer to our complete analysis for Johnson & Johnson
See More at Trefis | View Interactive Institutional Research (Powered by Trefis)